Literature DB >> 8894147

Bone remodeling alterations in myelodysplastic syndrome.

L Mellibovsky1, A Diez, S Serrano, J Aubia, E Pérez-Vila, M L Mariñoso, X Nogués, R R Recker.   

Abstract

There is a close relationship between hematopoietic bone marrow and bone cells. Thus, the profound derangement of hematopoiesis in myelodysplastic syndromes (MDS) might be expected to affect bone cell function. We studied the dynamic histomorphometric changes in bone in 22 MDS patients to examine this relationship and analyze the influence of hematological disease on bone remodeling. Bone-regulating hormones and histomorphometry of undecalcified transiliac bone biopsies, after double tetracycline labeling, were studied. Serum calcium, phosphorus, creatinine, alkaline phophatase, osteocalcin, iPTH, 25(OH)D3, 1,25(OH)2D3, hydroxyprolinuria, and calcium/creatinine ratio in urine were normal compared with controls. Histomorphometry showed a significant decrease in osteoblast surface (Ob.S/BS) (0.30 +/- 0.40 vs. 0.8 +/- 1.1, p = 0.031), wall thickness (W.Th), (22.03 +/- 5.5 vs. 31.8 +/- 5.8, p < 0.005), osteoclast number (N.Oc/T.Ar) (0.004 +/- 0.01 vs. 0.017 +/- 0.01, p = 0.03), mineral apposition rate (MAR) (0.16 +/- 0.15 vs. 0.53 +/- 0.19, p < 0.005), bone formation rate, surface referent (BFR/BS) (0.004 +/- 0.10 vs. 0.016 +/- 0.016, p = 0.009), and activation frequency (Ac.f) (0.06 +/- 0.07 vs. 0.21 +/- 0.23, p = 0.008). An increase in mineralization lag time (MLT) (119.2 +/- 78.6 vs. 29.6 +/- 77, p < 0.005), (mean +/- SD, unpaired Student t-test) was observed. Bone volume (BV/ TV), eroded surfaces (ES/BS), and osteoid thickness (O.Th) remained unchanged. This picture of adynamic bone with decreased mineral apposition rate and markedly decreased osteoclast number is a characteristic finding in MDS patients. Thus, bone histomorphometric finding in MDS patients show the relationships and interactions between hematopoietic and bone cells.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8894147     DOI: 10.1016/s8756-3282(96)00210-4

Source DB:  PubMed          Journal:  Bone        ISSN: 1873-2763            Impact factor:   4.398


  11 in total

1.  Mesenchymal stromal cells from patients with myelodyplastic syndrome display distinct functional alterations that are modulated by lenalidomide.

Authors:  Ruben A Ferrer; Manja Wobus; Catrin List; Rebekka Wehner; Claudia Schönefeldt; Barbara Brocard; Brigitte Mohr; Martina Rauner; Marc Schmitz; Maik Stiehler; Gerhard Ehninger; Lorenz C Hofbauer; Martin Bornhäuser; Uwe Platzbecker
Journal:  Haematologica       Date:  2013-05-28       Impact factor: 9.941

2.  Impaired osteogenic differentiation of mesenchymal stem cells derived from bone marrow of patients with lower-risk myelodysplastic syndromes.

Authors:  Chengming Fei; Youshan Zhao; Shucheng Gu; Juan Guo; Xi Zhang; Xiao Li; Chunkang Chang
Journal:  Tumour Biol       Date:  2014-01-19

Review 3.  The microenvironment in myelodysplastic syndromes: Niche-mediated disease initiation and progression.

Authors:  Allison J Li; Laura M Calvi
Journal:  Exp Hematol       Date:  2017-08-18       Impact factor: 3.084

4.  Machine Learning of Bone Marrow Histopathology Identifies Genetic and Clinical Determinants in Patients with MDS.

Authors:  Oscar E Brück; Susanna E Lallukka-Brück; Helena R Hohtari; Aleksandr Ianevski; Freja T Ebeling; Panu E Kovanen; Soili I Kytölä; Tero A Aittokallio; Pedro M Ramos; Kimmo V Porkka; Satu M Mustjoki
Journal:  Blood Cancer Discov       Date:  2021-03-22

Review 5.  Senescent Mesenchymal Stem Cells in Myelodysplastic Syndrome: Functional Alterations, Molecular Mechanisms, and Therapeutic Strategies.

Authors:  Xiaofang Chen; Ningyu Li; Jianyu Weng; Xin Du
Journal:  Front Cell Dev Biol       Date:  2021-02-11

6.  Bone progenitor dysfunction induces myelodysplasia and secondary leukaemia.

Authors:  Marc H G P Raaijmakers; Siddhartha Mukherjee; Shangqin Guo; Siyi Zhang; Tatsuya Kobayashi; Jesse A Schoonmaker; Benjamin L Ebert; Fatima Al-Shahrour; Robert P Hasserjian; Edward O Scadden; Zinmar Aung; Marc Matza; Matthias Merkenschlager; Charles Lin; Johanna M Rommens; David T Scadden
Journal:  Nature       Date:  2010-03-21       Impact factor: 49.962

Review 7.  Myelodysplasia is in the niche: novel concepts and emerging therapies.

Authors:  E Bulycheva; M Rauner; H Medyouf; I Theurl; M Bornhäuser; L C Hofbauer; U Platzbecker
Journal:  Leukemia       Date:  2014-11-14       Impact factor: 11.528

Review 8.  Beyond the Niche: Myelodysplastic Syndrome Topobiology in the Laboratory and in the Clinic.

Authors:  Eugenia Flores-Figueroa; Dita Gratzinger
Journal:  Int J Mol Sci       Date:  2016-04-13       Impact factor: 5.923

Review 9.  Immune Dysfunction, Cytokine Disruption, and Stromal Changes in Myelodysplastic Syndrome: A Review.

Authors:  Olivia F Lynch; Laura M Calvi
Journal:  Cells       Date:  2022-02-08       Impact factor: 6.600

Review 10.  Increasing Complexity of Molecular Landscapes in Human Hematopoietic Stem and Progenitor Cells during Development and Aging.

Authors:  Suzanne M Watt; Peng Hua; Irene Roberts
Journal:  Int J Mol Sci       Date:  2022-03-27       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.